RCKT

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is a clinical-stage biotechnology company founded in 2015 and headquartered in Cranbury, New Jersey. The company specializes in developing gene therapies for rare and devastating genetic diseases, operating as a multi-platform biotechnology enterprise with both ex vivo and in vivo gene therapy programs. Since its initial public offering in February 2015, Rocket has focused exclusively on advancing innovative treatments for patients with limited therapeutic options, particularly those suffering from rare genetic disorders affecting blood cells, immune function, and organ systems.